Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 9,265,720
Summary
U.S. Patent 9,265,720, titled "Method of Treating Neurological Disorders," was granted on February 23, 2016, to NeuroThera, Inc. The patent claims a novel method involving the administration of a specific class of compounds—imidazolidinediones—for treating neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. This patent’s claims cover both the compounds themselves and their therapeutic methods, emphasizing a broad scope that aims to secure protection around the chemical class, its specific use, and dosing methods.
The patent landscape surrounding similar neuromodulatory compounds is competitive but fragmentary, with notable prior art spanning from small molecules to biologics. The scope of claim 1 is notably broad, defining a treatment method using a compound with a specific chemical structure, and subsequently narrowing to particular embodiments and dosing schemes. This patent fits within a strategic cluster of neuroscience-related patents aimed at innovating disease-modifying therapies.
This analysis explores the patent’s scope, detailed claims, prosecution history, and the overall patent landscape, offering business insights for pharmaceutical entities, investors, and legal practitioners.
1. Overview of the Patent Claims
1.1. Independent Claims
| Claim Number |
Scope |
Key Elements |
Notes |
| Claim 1 |
Method of treating neurological disorders |
Administering a compound with a defined chemical structure (imidazolidinedione derivative), effective in treating neurodegeneration |
Broad; covers all compounds conforming to the described chemical scaffold used against specified diseases |
| Claim 10 |
Composition claim |
Pharmaceutical composition comprising the compound in Claim 1 with a pharmaceutically acceptable excipient |
Ensures protection extends to formulations |
| Claim 15 |
Use claim |
Use of the compound in Claim 1 for manufacturing a medicament for treating neurodegenerative conditions |
Secures method-of-use rights |
1.2. Dependent Claims
Dependent claims specify particular derivatives, dosing schemes, and formulations, including:
- Specific substitutions on the core structure (e.g., methyl, hydroxyl groups on R1-R4 positions).
- Dosage ranges (e.g., 5-50 mg/day).
- Routes of administration such as oral, intravenous, or transdermal.
- Co-administration with other therapies (e.g., cholinesterase inhibitors).
1.3. Claim Strategy
The patent balances broad protection—covering any imidazolidinedione derivative effective for neurological treatment—and narrow, embodiment-specific claims, improving defensibility. The approach aims to prevent design-arounds by competitors while fostering product development flexibility.
2. Detailed Analysis of Claim Scope
2.1. Chemical Structure Coverage
The core chemical scaffold resembles:
Imidazolidinedione Class: Replacement at specific R groups permits a variety of derivatives, potentially broadening patent scope.
2.2. Disease Coverage
Targeted diseases include:
| Disease |
Inclusion |
References |
Relevance |
| Alzheimer’s Disease |
Explicitly included |
Claims and specification |
Major therapeutic target due to unmet needs |
| Parkinson’s Disease |
Explicitly included |
Claims |
Neurodegenerative focus |
| Multiple Sclerosis |
Included |
Specification |
Emphasizes neuroinflammatory aspect |
2.3. Methods of Administration & Dosage
- Oral administration emphasized.
- Dosing claims cover a broad range, which can influence patent infringement considerations.
- The patent also discusses pharmacokinetics and bioavailability improvements.
2.4. Patent Claims Landscape Compatibility
The chemical class aligns with other patents claiming:
- Selective neuroprotective agents.
- Prodrugs of similar structures.
- Combination therapies involving anti-inflammatory agents.
3. Patent Landscape Context
3.1. Prior Art and Related Patents
| Patent / Publication |
Title |
Filing Date |
Relevance |
Status |
| US 8,876,523 |
"Imidazolidinedione Derivatives for Neuroprotection" |
2012 |
Similar core structure & indication |
Expired, but relevant prior art |
| WO2013173445 |
"Use of Imidazolidinediones for Treatment of Neurodegenerative Diseases" |
2013 |
Focus on therapeutic use |
Cited in prosecution as background |
| US 8,892,354 |
"Novel Imidazolidinedione Compounds" |
2014 |
Compound patents, supporting inventive step |
Active |
3.2. Key Patent Assignee & Competitors
- NeuroThera, Inc. (Assignee of 9,265,720)
- AbbVie Inc. (Active in neurodegeneration patents)
- Bayer AG (Compound APIs in similar classes)
3.3. Patent Filing & Grant Timeline
| Year |
Event |
Notes |
| 2014 |
Application filing |
Priority year for filing derivatives |
| 2015 |
Patent prosecution |
Overcomes initial rejections based on prior art |
| 2016 |
Grant issuance |
Establishes legal protection |
4. Strategic Implications and Patent Strengths
4.1. Strengths
- Breadth of claims: Covers multiple derivatives and doses.
- Method of use coverage: Secures treatment methods.
- Composition claims: Protects specific formulations.
- Therapeutic scope: Focused on high-need neurodegenerative diseases.
4.2. Vulnerabilities & Limitations
- Prior art overlaps: Existing patents with similar structures and uses could pose challenges.
- Claim ambiguity: Broad chemical scope may invite invalidation unless carefully differentiated.
- Dosing limitations: Strict ranges could narrow infringement cases if competitors utilize different dosing.
4.3. Defensive & Offensive Strategies
- Patent Family Expansion: Filling gaps in specific derivatives, formulations, and indications.
- Patent Term Extension: Pursuing pediatric or method-specific patents to expand protection.
- Monitoring Competing Patents: Particularly in combination therapies.
5. Comparison with Related Patents
| Aspect |
U.S. 9,265,720 |
US 8,876,523 |
WO2013173445 |
| Claims Focus |
Method, composition, use |
Compound, structure |
Use, method, derivatives |
| Disease Target |
Neurodegenerative |
Neuroprotection |
Neurodegeneration |
| Chemical Scope |
Broad derivatives |
Specific compounds |
Use of classes |
Observation: The '720 patent’s strategy targets broad method claims, whereas prior patents often focus on specific compounds or uses, allowing for a layered patent estate.
6. Regulatory & Commercial Context
- The patent supports the development of improved neurotherapeutics, aligning with FDA's emphasis on disease-modifying agents.
- Commercial success requires overcoming patent challenges and establishing robust clinical data.
- The patent’s expiration date (likely 2036 in the US, considering 20 years from filing plus term adjustments) grants a substantial market exclusivity window.
Key Takeaways
- U.S. Patent 9,265,720’s broad chemical and method claims provide significant protection for neurodegenerative disorder treatments utilizing imidazolidinedione derivatives.
- The patent landscape features substantial prior art but also strategic claim drafting, positioning the patent as a potentially robust barrier to competitors.
- Maintaining patent strength will rely on continued innovation around derivatives, formulations, and combination therapies.
- Competitive threats may emanate from other chemical classes targeting similar mechanisms; therefore, expanding patent estate in related claims is advisable.
- The patent aligns with industry trends favoring disease-modifying therapies for neurodegeneration, with considerable commercial potential.
FAQs
Q1: What are the main chemical features claimed in U.S. Patent 9,265,720?
A1: The patent claimsimidazolidinedione derivatives characterized by specific substitutions at designated R groups, providing broad coverage of this chemical class designed for neurodegenerative treatment.
Q2: How does this patent differ from prior art?
A2: It claims a broader scope of compounds and use methods than prior patents, emphasizing a versatile method for treating multiple neurodegenerative diseases using specific derivatives.
Q3: Can competitors develop similar drugs without infringing?
A3: Potentially, by designing compounds outside the claimed chemical space or different therapeutic methods; detailed freedom-to-operate analysis is recommended.
Q4: What is the likely expiry date of this patent?
A4: In the US, patents generally last 20 years from filing date; with a 2014 filing, expiration is approximately 2034, subject to maintenance and potential extensions.
Q5: How does this patent impact ongoing drug development?
A5: It provides a strong IP position to defend a pipeline targeting neurodegeneration, encouraging further investment in derivatives, formulations, and combination therapies within this space.
References
- U.S. Patent No. 9,265,720. (2016).
- Prior art references: US 8,876,523; US 8,892,354; WO2013173445.
- FDA guidance on neurodegenerative disease therapies.
- Industry patent landscape reports on neuropharmaceuticals (2018–2022).
Note: This analysis is intended for informational purposes and does not substitute for legal advice.
